Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May;204(5):1811-1815.
doi: 10.1111/bjh.19286. Epub 2024 Jan 3.

Real-world efficacy of single-agent belantamab mafodotin in relapsed systemic AL amyloidosis

Jahanzaib Khwaja  1 , Joshua Bomsztyk  2 , Maria Atta  3 , Ceri Bygrave  4 , Adam Forbes  5 , Senthil Durairaj  6 , Savio Fernandes  7 , James Taylor  8 , Pamela Paterson  9 , Gillian Brearton  10 , Charles Crawley  11 , Oonagh Sheehy  12 , Rachel Brown  13 , Richard Soutar  14 , Mamta Garg  15 , Andrzej Rydzewski  16 , Krzysztof Jamroziak  17 , Shameem Mahmood  1   2 , Ashutosh D Wechalekar  1   2
Affiliations

Real-world efficacy of single-agent belantamab mafodotin in relapsed systemic AL amyloidosis

Jahanzaib Khwaja et al. Br J Haematol. 2024 May.

Abstract

Systemic light chain (AL) amyloidosis is a relapsing plasma cell disorder. Therapy is limited, particularly for triple-class refractory disease. We report the use of belantamab mafodotin, a BCMA-directed drug-antibody conjugate, for relapsed AL amyloidosis, including patients traditionally excluded from clinical trials. Thirty-one patients were reviewed, with a median of three prior lines of therapy. The median follow-up was 12 months (95% CI 4-19), and a median of five doses were delivered. The best haematological overall response rate was 71%, and the complete/very good partial response was 58%. Sixty-eight percent had keratopathy and improved in all. Belantamab mafodotin has high efficacy and good tolerability in patients with relapsed AL amyloidosis.

Keywords: amyloidosis; antibody therapy; immunotherapy.

PubMed Disclaimer

References

REFERENCES

    1. Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM‐2): a two‐arm, randomised, open‐label, phase 2 study. Lancet Oncol. 2020;21(2):207–221.
    1. Khwaja J, Bomsztyk J, Mahmood S, Wisniowski B, Shah R, Tailor A, et al. High response rates with single‐agent belantamab mafodotin in relapsed systemic AL amyloidosis. Blood Cancer J. 2022;12:128.
    1. Palladini G, Schönland SO, Sanchorawala V, Kumar S, Wechalekar A, Hegenbart U, et al. Clarification on the definition of complete haematologic response in light‐chain (AL) amyloidosis. Amyloid. 2021;28(1):1–2.
    1. Milani P, Basset M, Russo F, Foli A, Merlini G, Palladini G. Patients with light‐chain amyloidosis and low free light‐chain burden have distinct clinical features and outcome. Blood. 2017;130(5):625–631.
    1. Farooq AV, Degli Esposti S, Popat R, Thulasi P, Lonial S, Nooka AK, et al. Corneal epithelial findings in patients with multiple myeloma treated with antibody‐drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM‐2 study. Ophthalmol Ther. 2020;9(4):889–911.

Substances

LinkOut - more resources